Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation.
about
Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizonHepatitis B and Hepatitis C Reactivation in the Biologic EraCardiac allograft vasculopathy: diagnosis, therapy, and prognosis.Association of Hepatitis C Virus Seropositivity With Inflammatory Markers and Heart Failure in Persons With Coronary Heart Disease: Data From the Heart and Soul StudyDiagnosis, management, and treatment of hepatitis C: an updateHepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.Thrombocytopenia in patients with chronic hepatitis C: a possible role of HCV on platelet progenitor cell maturation.Platelets and infection - an emerging role of platelets in viral infection.Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donorsAll-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantationShould we consider patients with coexistent hepatitis B or C infection for orthotopic heart transplantation?Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytesA concise review of hepatitis C in heart and lung transplantation.Factors associated with the development of cardiac allograft vasculopathy--a systematic review of observational studies.Risk factors of cardiac allograft vasculopathy.Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.Determination of the impact of hepatitis C virus on insulin resistance and arterial stiffness in hemodialysis patients.Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.Donor selection in the modern era.The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients.
P2860
Q26773201-0FF360BD-6A5F-45CA-A933-5368F5B7A39EQ26781993-55B15957-7C25-4AB6-B9E1-DE43B372A95EQ27011330-B3D8F4C9-E18C-432D-BF2B-323AD48C506CQ27490429-4882DE9C-D209-4C72-90DE-E474F8CF6C3DQ29619682-5DFF6ECC-0DE9-4BD9-97CA-E637ED9FEBC8Q30360538-3ECD66A7-0D9C-48B8-A5A5-07DAB5E33A32Q33242978-67415371-B190-4D84-891C-50342EABECEAQ33385876-CEE038EB-3272-46EA-B4C7-01FB0776AD08Q33419642-AAA13B9E-8975-4F33-A097-407C9321F0E2Q33803919-A7A4777D-14A8-4CBD-BAE3-DD12E62874BFQ35974996-EECBBF8A-7B1E-464F-8A28-6C5EB4BEA44AQ36909187-61E1EF39-A5C4-4113-90C3-F49BFB107C5EQ37338207-F1FD3BBC-15C9-4300-B9FE-31306390AB2DQ37607859-CFD456C3-B111-4AB0-93A0-2C727018B945Q37931020-FEA01671-098D-409C-9370-A07809989552Q37968277-B27FB8FD-F38F-4110-99E1-25EB8E369FA2Q40800486-CDFDF555-8748-4CD7-B49B-AB49978F153FQ41109284-F072FD34-F4AE-4B8E-B5B8-50FE6A440079Q42979347-B50AD2AA-D07A-4B1A-97F1-23135E52288FQ48302077-1DC72DD3-C094-4ADA-BEC8-4C0B1B910D6FQ54936300-DACA4DCD-6671-4611-BACC-C46AD83150A9Q55113960-3D98C11D-FC3A-4EEF-BF9F-29B19C1027D5
P2860
Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@en
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@nl
type
label
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@en
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@nl
prefLabel
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@en
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@nl
P2093
P1476
Donor hepatitis-C seropositivi ...... after cardiac transplantation.
@en
P2093
Daniel J Cook
E Murat Tuzcu
James B Young
Mohamad H Yamani
Norman B Ratliff
Patrick M McCarthy
Robin K Avery
Showkat A Haji
Steven Mawhorter
P304
P356
10.1016/S1053-2498(03)00148-7
P577
2004-03-01T00:00:00Z